Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar;95(3):312-7.
doi: 10.1080/08035250500423804.

Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease

Anders Erikson  1 , Håkan Forsberg, Magnus Nilsson, Marianne Aström, Jan-Eric Månsson
Affiliations

Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease

Anders Erikson et al. Acta Paediatr. 2006 Mar.

Abstract

Aim: To study the long-term effects of enzyme replacement therapy on the neurological signs of chronic neuronopathic Gaucher disease and to evaluate some biochemical parameters for monitoring the treatment.

Methods: Eight patients from the Norrbottnian cohort were followed during 10 y of treatment. They were followed with regular clinical observations, biochemical tests and psychometric testing.

Results: After the start of treatment, their general well-being improved and was stable during the follow-up. In three of the patients there were some indications of slow neurological deterioration. The mean results of psychometric testing did not decrease. Glucosylceramide and chitotriosidase levels were useful in monitoring the treatment. The chemokine CCL18 also seems to be a useful parameter for future monitoring.

Conclusions: Enzyme replacement therapy seems to slow down further neurological and mental deterioration in mild chronic neuronopathic (type 3) Gaucher disease.

PubMed Disclaimer

Publication types